Ignet

Gene Information

Gene symbol: EPO

Gene name: erythropoietin

HGNC ID: 3415

Synonyms: EP

Related Genes

#	Gene Symbol	Number of hits
1	ADIPOQ	1 hits
2	AKT1	1 hits
3	ALB	1 hits
4	BCL2	1 hits
5	BCL2L1	1 hits
6	BDNF	1 hits
7	CNTF	1 hits
8	CRP	1 hits
9	CYCS	1 hits
10	EPOR	1 hits
11	FOXO3	1 hits
12	GSK3B	1 hits
13	HBA1	1 hits
14	HBB	1 hits
15	HIF1A	1 hits
16	IGF1	1 hits
17	IL1B	1 hits
18	IL2	1 hits
19	IL6	1 hits
20	INS	1 hits
21	JAK2	1 hits
22	LEP	1 hits
23	MAPK1	1 hits
24	MVD	1 hits
25	NFKB1	1 hits
26	NOS2A	1 hits
27	NOS3	1 hits
28	PIK3CA	1 hits
29	RETN	1 hits
30	TFPI	1 hits
31	TNF	1 hits
32	VEGFA	1 hits
33	VHL	1 hits
34	WNT1	1 hits

Related Sentences

#	PMID	Sentence
1	2245040	A monoclonal antibody to IGF-I reduced the effect of IGF-I by 50-80%, had no effect on Epo, and abolished the GH effect.
2	7677965	Recombinant erythropoietin increases the number of reticulocytes containing fetal hemoglobin in laboratory animals and in humans.
3	7677965	We studied whether hydroxyurea and erythropoietin might have a potentiating effect on the production of fetal hemoglobin in patients with sickle cell disease.
4	8420356	The increase in fetal hemoglobin may be the consequence of increased erythropoiesis, mediated by either erythropoietin or hyperinsulinemia.
5	8105957	The infrequent EPO group required only 35% as much EPO as the frequent group to maintain hemoglobin and hematocrit, which were significantly greater.
6	7857436	In this study we determine the erythropoietin levels and hematocrit in 22 women with preterm labor, 21 with insulin-dependent diabetes, 22 with preeclampsia, and 20 with normal gestation.
7	7659529	Erythropoietin (Epo), the primary regulator of the production of erythroid cells, acts by binding to a cell surface receptor (EpoR) on erythroid progenitors.
8	10624788	The serum Epo concentrations of diabetic patients (17.6 +/- 8.1 mIU/ml) were significantly lower than those of non-diabetic patients with similar degree of decrease in hemoglobin concentrations (144.9 +/- 108.0 mIU/ml, P<0.001).
9	12084725	Gel shift assays with a (32)P-labeled leptin promoter -116/HRE probe and nuclear extracts from hypoxia-treated cells indicated binding of the HIF1alpha/beta heterodimer, which was blocked with an excess of unlabeled -116/HRE probe or a HIF1-binding probe from the erythropoietin gene enhancer.
10	14718755	Cord serum CRP correlated positively with amniotic fluid erythropoietin and umbilical artery pCO2.
11	15754279	Detailed data were collected: demographics; cause of renal failure; time on dialysis therapy; type of membrane; erythropoietin treatment; body mass index (BMI); predialysis albumin, prealbumin, and bicarbonate levels; and outcome.
12	16132904	Serum Epo levels were also negatively correlated with the percentage of glycosylated Hb, HbA1(C) (r=-0.446), and the correlation was stronger with the ln of serum Epo (r=-0.638, p<0.001).
13	17229797	To investigate the expression of the hypoxia-inducible factor-1alpha (HIF-1alpha) and the protein products of its target genes vascular endothelial growth factor (VEGF), erythropoietin (Epo) and angiopoietins (Angs), and the antiangiogenic pigment epithelium-derived factor (PEDF) in proliferative diabetic retinopathy (PDR) epiretinal membranes.
14	17671395	We designed a study to evaluate whether erythropoietin (EPO), given to patients on continuousambulatory peritoneal dialysis (CAPD) both with and without diabetes mellitus (DM), influences tissue factor (TF), tissue factor pathway inhibitor (TFPI) and oxidative stress (SOX).
15	17671395	Multivariate analysis showed that independent variables linked to TFPI levels in diabetic patients were Cu/Zn SOD, Ht and EPO dose.
16	17522145	The in vivo evidence in this study suggests that Epo in the vitreous binds to EpoR in PDR membranes, which subsequently leads to the proliferation of new retinal vessels.
17	18473829	Erythropoietin controls a variety of signal transduction pathways during oxidative stress that can involve Janus-tyrosine kinase 2, protein kinase B, signal transducer and activator of transcription pathways, Wnt proteins, mammalian forkhead transcription factors, caspases, and nuclear factor kappaB.
18	19755525	Administration of erythropoietin (EPO) induced phosphorylation of Akt and GSK-3beta and reduced infarct size (% risk area) from 47.4 +/- 5.2% to 23.9 +/- 3.5% in LETO hearts.
19	19755525	However, neither phosphorylation of Akt and GSK-3beta nor infarct size limitation was induced by EPO in OLETF rats.
20	19755525	TUDCA restored responses of GSK-3beta, mPTP opening threshold, and infarct size to EPO receptor activation in OLETF rats.
21	19755525	Disruption of protective signals leading to GSK-3beta phosphorylation and increase in mitochondrial GSK-3beta are dual mechanisms by which increased ER stress inhibits EPO-induced suppression of mPTP opening and cardioprotection in diabetic hearts.
22	20030977	To explore and evaluate the protective effect of erythropoietin (EPO) on retinal albumin leakage of streptozotocin-induced diabetic rats, an algorithm based on Beer-Lambert's law is presented.
23	19626038	This increased rate of closure of the two EPO-treated wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of apoptosis.
24	19815604	In a rat model of streptozotocin-induced DM, we investigated, by pre-embedding electron-immunocytochemistry, whether epoetin delta affects DM-induced structural changes in cerebrovascular endothelium of the rat basilar artery and influences the subcellular distribution of endothelial nitric oxide synthase (eNOS).
25	19815604	Epoetin delta treatment influenced DM-induced changes to the distribution of eNOS in, and the structure of, the endothelial cell.
26	20112184	Decrease of hemoglobin occurs in diabetic patients with nephropathy earlier than in nondiabetic patients, probably due to impaired synthesis of erythropoietin (EPO).
27	20515763	Exogenous EPO at pharmacologic levels leads to suppression of VEGF and in turn, restoration of the normal functions of BRB in a time-dependent manner.
28	20515763	In the diabetic retina, the same level of exogenous EPO that inhibits VEGF also exerted neuronal protection.
29	20685070	Here, we report that renal tubular cells possess EPOR and that EPO reduces high glucose-induced oxidative stress in renal tubular cells.
30	20685070	Further, we found that EPO inhibited high glucose-induced renal tubular cell apoptosis and that this protective effect was dependent on reduction of Bax/caspase-3 expression as well as elevation of Bcl-2 expression.
31	20685070	Our results suggest that EPO can inhibit high glucose-induced renal tubular cell apoptosis through direct effect on anti-oxidative stress and that EPOR may play a key role in this process.
32	21176750	Average hemoglobin (Hb) levels during the 12-month study period were significantly lower in the diabetes group than in the non-diabetes group, and a higher dose of EPO was required in the diabetes group.
33	21176750	Insulin resistance as established by HOMA-IR and adiponectin was associated with EPO responsiveness in HD patients.
34	21176750	For improvement in EPO response, insulin resistance may be a new target for treating HD patients.
35	20981553	In hearts from healthy controls, EPO decreased infarct size (14.36��0.60 and 36.22��4.20% of left ventricle in EPO-treated and untreated hearts, respectively, p�<�0.05) and increased phosphorylated forms of Akt, ERK1/2, and their downstream target GSK-3?.
36	20981553	In hearts from STZ-induced diabetic rats, EPO did not decrease infarct size (32.05��2.38 and 31.88��1.87% in EPO-treated and untreated diabetic rat hearts, respectively, NS) nor did it increase phosphorylation of Akt, ERK1/2, and GSK-3?.
37	20981553	In contrast, in hearts from HFD-induced insulin resistance rats, EPO decreased infarct size (18.66��1.99 and 34.62��3.41% in EPO-treated and untreated HFD rat hearts, respectively, p�<�0.05) and increased phosphorylation of Akt, ERK1/2, and GSK-3?.
38	18235022	Within 2 weeks of the onset of diabetes, activation of the ERK but not the STAT5 pathway was detected in the diabetic retina treated with EPO.
39	21298620	There was also a significant association between EPO dosage and homeostasis model assessment for insulin resistance (HOMA-IR), hs-CRP, IL-6, tumor necrosis factor a, leptin, and HMW adiponectin levels in DM patients with MIA syndrome.
40	19040789	EPO receptor (EPOR) expression is also found in endothelial, brain, cardiovascular and other tissues, although at levels considerably lower than that of erythroid progenitor cells.
41	21242957	Given that erythropoietin (EPO) is a target gene of the HIF pathway, which is not expressed in islets, we tested whether activating EPO signaling by systemic administration with recombinant human EPO (rHuEPO) can overcome the ?-cell defects that occurred with VHL loss.
42	21324713	Western blot of phospho-eNOS (serine1177) and eNOS and was significantly induced by hypoxia but not after EPO treatment.
43	21324713	However, iNOS increased at hypoxia and with EPO stimulation compared to normal oxygen tension.
44	21443457	EPO modulates the expression of Wnt1 and utilizes Wnt1 to confer EC protection during elevated D-glucose exposure, since application of a Wnt1 neutralizing antibody, treatment with the Wnt1 antagonist DKK-1, or gene silencing of Wnt1 with Wnt1 siRNA transfection abrogates the protective capability of EPO.
45	21443457	EPO through a novel Wnt1 dependent mechanism controls the post-translational phosphorylation of the "pro-apoptotic" forkhead member FoxO3a and blocks the trafficking of FoxO3a to the cell nucleus to prevent apoptotic demise.
46	21443457	EPO also employs the activation of protein kinase B (Akt1) to foster phosphorylation of GSK-3? that appears required for EPO vascular protection.
47	21443457	Subsequently, we show that EPO requires modulation of both Wnt1 and FoxO3a to oversee mitochondrial membrane depolarization, cytochrome c release, and caspase activation during elevated D-glucose.
48	20973890	Genes encoding inflammatory factors, such as interleukin-2 and interleukin-11, which were upregulated in the diabetic retinas, were restored after erythropoietin treatment.
49	20973890	Genes encoding pro-apoptotic effectors, like Tnfrsf5, Bid3 and Bcl2l1, were also upregulated in diabetic rats and attenuated in erythropoietin-treated group.
50	21566300	The prevalence was also elevated for the hemoglobin levels below 11 g/dL (the minimum hemoglobin level at which therapy should be initiated with erythropoietin), that is, 21%, 17%, 31%, 49%, and 72%, respectively for stages from 1 to 5.
51	21196299	The elevated TNF-alpha and IL-1beta, but not IL-6 and VEGF, were decreased by 2 U/ml EPO as detected by real-time PCR and ELISA.
52	21196299	Moreover, the activity of AP-1 but not NF-kappaB was modulated by glyoxal and EPO.
53	21196299	Intravitreal injection of EPO performed 24 h prior to sacrifice significantly reduced TNF-alpha and IL-1beta production while moderately attenuating IL-6 and VEGF in the retinas of streptozotocin-induced diabetic rats.
54	21734083	Elevated EPO levels were independently associated with elevated C-reactive protein, low ferritin, and hypertension, in a multivariate model that also included age, cardiovascular disease, kidney function, albumin, cholesterol, and hemoglobin.
55	21754921	We aimed to investigate whether CNTO 530, a novel Epo receptor agonist, could affect glucose tolerance and insulin sensitivity.
56	21778676	EPO resistance is associated with low body mass index (BMI) (coefficient ? =-0.393, p = 0.002) and with high serum resistin levels (coefficient ? = 0.332, p = 0.018).
57	17402563	Finally, we found that erythropoietin is an ischemia-induced angiogenic factor that acts independently and as potently as VEGF in proliferative diabetic retinopathy (PDR).
58	21620963	In addition, Epo was able to increase cytosolic Ca(2+) with dependence on extracellular calcium influx and this effect was blocked by either JAK2 or PI3K inhibition.
59	17691973	Intimately linked to this cytoprotection is the downstream Wnt1 pathway of glycogen synthase kinase (GSK-3beta) that requires phosphorylation of GSK-3beta and inhibition of its activity by EPO.
60	21819507	EPO is locally expressed and is correlated with VEGF in eyes with diabetic macular oedema.
61	17482474	Multi-tissue erythropoietin receptor (EPO-R) expression provides for erythropoietin (EPO) activity beyond its known regulation of red blood cell production.
62	21622158	The results showed that intravitreal EPO ameliorated the up-regulation of GFAP and vimentin in the diabetic retina evaluated by immunofluorescence and Western blotting; but up-regulated BDNF and CNTF expressions, quantified by real-time PCR and ELISA, in the 24-week diabetic rat retinas.
63	21622158	In vitro, BDNF and CNTF expressions were stimulated by EPO through both extracellular signal-regulated kinase1/2 (ERK1/2) and Akt pathways.
64	21622158	BDNF was involved in EPO-induced neurite outgrowth of primary rat retinal neurons.
65	22044999	Although erythropoietin (Epo) is the cytokine known to regulate erythropoiesis, erythropoietin receptor (EpoR) expression and associated activity beyond haematopoietic tissue remain uncertain.
66	22044999	Although Epo treatment in WT-mice induces the expression of the polypeptide hormone precursor, POMC, mice lacking EpoR show reduced levels of POMC in the hypothalamus.
67	22044999	This study provides the first evidence that mice lacking EpoR in non-haematopoietic tissue become obese and insulin resistant with loss of Epo regulation of energy homeostasis.